Evidence map›Paper›PMID 28569218›Full record

ArticleBreast cancer research : BCR2017

A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data.

Giorgio E M Melloni, Luca Mazzarella, Loris Bernard, Margherita Bodini, Anna Russo, Lucilla Luzi, Pier Giuseppe Pelicci, Laura Riva

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Ret Receptor Has Distinct Alterations and Functions in Breast Cancer.Journal of mammary gland biology and neoplasia · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Giorgio E M MelloniCenter for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia, Via Adamello 16, Milan, Italy.
Luca MazzarellaDepartment of Experimental Oncology, European Institute of Oncology, Via Adamello 16, Milan, Italy.
Loris BernardClinical Genomics Lab, European Institute of Oncology, via Ripamonti 435, Milano, Italy.
Margherita BodiniCenter for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia, Via Adamello 16, Milan, Italy.
Anna RussoDepartment of Experimental Oncology, European Institute of Oncology, Via Adamello 16, Milan, Italy.
Lucilla LuziDepartment of Experimental Oncology, European Institute of Oncology, Via Adamello 16, Milan, Italy.
Pier Giuseppe PelicciDepartment of Experimental Oncology, European Institute of Oncology, Via Adamello 16, Milan, Italy.
Laura RivaCenter for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia, Via Adamello 16, Milan, Italy. laura.riva@iit.it.ORCID 0000-0001-5688-4915

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe landscape of cancer-predisposing genes has been extensively investigated in the last 30 years with various methodologies ranging from candidate gene to genome-wide association studies. However, sequencing data are still poorly exploited in cancer predisposition studies due to the lack of statistical power when comparing millions of variants at once.

methodTo overcome these power limitations, we propose a knowledge-based framework founded on the characteristics of known cancer-predisposing variants and genes. Under our framework, we took advantage of a combination of previously generated datasets of sequencing experiments to identify novel breast cancer-predisposing variants, comparing the normal genomes of 673 breast cancer patients of European origin against 27,173 controls matched by ethnicity.

resultsWe detected several expected variants on known breast cancer-predisposing genes, like BRCA1 and BRCA2, and 11 variants on genes associated with other cancer types, like RET and AKT1. Furthermore, we detected 183 variants that overlap with somatic mutations in cancer and 41 variants associated with 38 possible loss-of-function genes, including PIK3CB and KMT2C. Finally, we found a set of 19 variants that are potentially pathogenic, negatively correlate with age at onset, and have never been associated with breast cancer.

conclusionsIn this study, we demonstrate the usefulness of a genomic-driven approach nested in a classic case-control study to prioritize cancer-predisposing variants. In addition, we provide a resource containing variants that may affect susceptibility to breast cancer.

Indexed as

Genetic Predisposition to DiseaseGenetic VariationGenome-Wide Association StudyAge FactorsAllelesBiomarkers, TumorBreast NeoplasmsCase-Control StudiesEpistasis, GeneticFemaleGene FrequencyGenes, BRCA1Genes, BRCA2GenotypeGerm-Line MutationHumansBiomarkers, TumorBreast cancerGermline mutationsPredispositionSomatic mutations

Identifiers

PMID28569218
PMCPMC5452392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.